Artículos por temáticas

Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease.

Plotkin JL, Day M, Peterson JD, Xie Z, Kress GJ, Rafalovich I, Kondapalli J, Gertler TS, Flajolet M, Greengard P, Stavarache M, Kaplitt MG, Rosinski J, Chan CS, Surmeier DJ.

Neuron. 2014 Jul 2;83(1):178-88. doi: 10.1016/j.neuron.2014.05.032.

Benign hereditary chorea: more than meets the eye.

Rice J.

Dev Med Child Neurol. 2014 Jul;56(7):606-7. doi: 10.1111/dmcn.12398. No abstract available.

The fate of cell grafts for the treatment of Huntington's disease: the post-mortem evidence.

Cisbani G, Cicchetti F.

Neuropathol Appl Neurobiol. 2014 Feb;40(1):71-90. doi: 10.1111/nan.12104. Review.

Prodromal Huntington disease as a model for functional compensation of early neurodegeneration.

Malejko K, Weydt P, Süßmuth SD, Grön G, Landwehrmeyer BG, Abler B.

PLoS One. 2014 Dec 26;9(12):e114569. doi: 10.1371/journal.pone.0114569.

Clinical and Neuroimaging Findings of Sydenham's Chorea.

Ekici A, Yakut A, Yimenicioglu S, Bora Carman K, Saylısoy S.

Iran J Pediatr. 2014 Jun;24(3):300-6.

Conventional and intravenous immunoglobulin therapy in paediatric antiphospholipid antibodies-related chorea.

Brogna C, Mariotti P, Manna R.

Lupus. 2014 Dec;23(14):1449-51. doi: 10.1177/0961203314551084. No abstract available.

A pilot study of virtual visits in Huntington disease.

Bull MT, Darwin K, Venkataraman V, Wagner J, Beck CA, Dorsey ER, Biglan KM.

J Huntingtons Dis. 2014;3(2):189-95. doi: 10.3233/JHD-140102.

Modulation at age of onset in tunisian huntington disease patients: implication of new modifier genes.

Hmida-Ben Brahim D, Chourabi M, Ben Amor S, Harrabi I, Trabelsi S, Haddaji-Mastouri M, Gribaa M, Sassi S, Gahbiche FE, Lamouchi T, Mougou-Zereli S, Ben Ammou S, Saad A.

Genet Res Int. 2014;2014:210418. doi: 10.1155/2014/210418.

Chorea, Hyperglycemia, Basal Ganglia Syndrome (C-H-BG) in an uncontrolled diabetic patient with normal glucose levels on presentation.

Bizet J, Cooper CJ, Quansah R, Rodriguez E, Teleb M, Hernandez GT.

Am J Case Rep. 2014 Apr 7;15:143-6. doi: 10.12659/AJCR.890179.

HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation.

Träger U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S, McKinnon C, Sirinathsinghji E, Kahlon S, Pfister EL, Moser R, Hummerich H, Antoniou M, Bates GP, Luthi-Carter R, Lowdell MW, Björk

Brain. 2014 Mar;137(Pt 3):819-33. doi: 10.1093/brain/awt355.

Abnormal resting-state connectivity of motor and cognitive networks in early manifest Huntington's disease.

Wolf RC, Sambataro F, Vasic N, Depping MS, Thomann PA, Landwehrmeyer GB, Süssmuth SD, Orth M.

Psychol Med. 2014 Nov;44(15):3341-56. doi: 10.1017/S0033291714000579.

The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation.

Papoutsi M, Labuschagne I, Tabrizi SJ, Stout JC.

Mov Disord. 2014 Apr 15;29(5):673-83. doi: 10.1002/mds.25864. Review.

Emotion perception and electrophysiological correlates in Huntington's disease.

Croft RJ, McKernan F, Gray M, Churchyard A, Georgiou-Karistianis N.

Clin Neurophysiol. 2014 Aug;125(8):1618-25. doi: 10.1016/j.clinph.2013.12.111.

Deep white matter in Huntington's disease.

Phillips O, Squitieri F, Sanchez-Castaneda C, Elifani F, Caltagirone C, Sabatini U, Di Paola M.

PLoS One. 2014 Oct 23;9(10):e109676. doi: 10.1371/journal.pone.0109676.

Genetic modifiers of Huntington's disease.

Gusella JF, MacDonald ME, Lee JM.

Mov Disord. 2014 Sep 15;29(11):1359-65. doi: 10.1002/mds.26001. Review.